{"classes":[{"categories":[{"measurements":[{"comment":"Upper confidence interval for PFS could not be obtained based on Kaplan-Meier estimates. Insufficient number of participants with events.","groupId":"OG000","lowerLimit":"4.2","upperLimit":"NA","value":"28.2"},{"comment":"Upper confidence interval for PFS could not be obtained based on Kaplan-Meier estimates. Insufficient number of participants with events.","groupId":"OG001","lowerLimit":"3.3","upperLimit":"NA","value":"28.2"},{"comment":"Median PFS could not be calculated and upper confidence interval was not obtained based on Kaplan-Meier estimates. Insufficient number of participants with events.","groupId":"OG002","lowerLimit":"2.8","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"21"}],"units":"Participants"}],"description":"Assessed using ACTG criteria. Summarized statistically using Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants enrolled into Cohort 4 and participants with evaluable HIV associated Kaposi sarcoma enrolled into Cohorts 1-3, who receive pembrolizumab IV over 30 minutes on day 1. Participants continue receiving their recommended combination antiretroviral therapy per established regimen. Cycles repeat every 21 days for up to 2 years or 35 doses in the absence of disease progression or unacceptable toxicity. Participants undergo physical examination and blood sample collection, and may undergo CT or PET/CT. Participants may also undergo biopsies during screening and on study.\n\nAntiretroviral Therapy: Given PO\n\nBiopsy: Undergo biopsy\n\nBiospecimen Collection: Undergo blood sample collection\n\nComputed Tomography: Undergo CT or PET/CT\n\nPembrolizumab: Given IV\n\nPositron Emission Tomography: Undergo PET/CT","id":"OG000","title":"Kaposi Sarcoma Cohort (Pembrolizumab and cART)"},{"description":"Treatment naïve participants enrolled into Cohort 4 and treatment naïve participants with evaluable HIV associated Kaposi sarcoma enrolled into Cohorts 1-3, who receive pembrolizumab IV over 30 minutes on day 1. Participants continue receiving their recommended combination antiretroviral therapy per established regimen. Cycles repeat every 21 days for up to 2 years or 35 doses in the absence of disease progression or unacceptable toxicity. Participants undergo physical examination and blood sample collection, and may undergo CT or PET/CT. Participants may also undergo biopsies during screening and on study.\n\nAntiretroviral Therapy: Given PO\n\nBiopsy: Undergo biopsy\n\nBiospecimen Collection: Undergo blood sample collection\n\nComputed Tomography: Undergo CT or PET/CT\n\nPembrolizumab: Given IV\n\nPositron Emission Tomography: Undergo PET/CT","id":"OG001","title":"Treatment Naïve Kaposi Sarcoma Cohort (Pembrolizumab and cART)"},{"description":"Previously treated participants enrolled into Cohort 4 and previously treated participants with evaluable HIV associated Kaposi sarcoma enrolled into Cohorts 1-3, who receive pembrolizumab IV over 30 minutes on day 1. Participants continue receiving their recommended combination antiretroviral therapy per established regimen. Cycles repeat every 21 days for up to 2 years or 35 doses in the absence of disease progression or unacceptable toxicity. Participants undergo physical examination and blood sample collection, and may undergo CT or PET/CT. Participants may also undergo biopsies during screening and on study.\n\nAntiretroviral Therapy: Given PO\n\nBiopsy: Undergo biopsy\n\nBiospecimen Collection: Undergo blood sample collection\n\nComputed Tomography: Undergo CT or PET/CT\n\nPembrolizumab: Given IV\n\nPositron Emission Tomography: Undergo PET/CT","id":"OG002","title":"Previously Treated Kaposi Sarcoma Cohort (Pembrolizumab and cART)"}],"paramType":"MEDIAN","populationDescription":"All participants who receive at least one dose of study drug. Participants without documented progressive disease or death will be censored at the last disease assessment date.\n\nPer the protocol, participants enrolled into Cohorts 1-3 were combined into one group for analysis. The number of participants enrolled to each cohort was not sufficient to perform subgroup analysis based on a CD4 count.","reportingStatus":"POSTED","timeFrame":"From the first dose of study drug to progressive disease or death, whichever occurs earlier, assessed up to 3 years","title":"Progression-free Survival (Kaposi Sarcoma Cohort)","type":"SECONDARY","unitOfMeasure":"months"}